Maj-Britt Jensen

15PUBLICATIONS
49CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsOncology and carcinogenesis not elsewhere classifiedRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 23, 2026
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1.

|May 23, 2025
Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study.

Aleksandar M Kostov, Maj-Britt Jensen, Bent Ejlertsen

|Apr 22, 2025
Statin Therapy in Early Breast Cancer: The MASTER Trial; A Randomized Phase III, Placebo-Controlled Comparison of Standard (Neo)Adjuvant Therapy Plus Atorvastatin versus Standard (Neo)Adjuvant Therapy Plus Placebo.

Signe Borgquist, Maj-Britt Jensen, Cecilie Linea Bendorff

|Mar 11, 2025
Prosigna Risk of Recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancer.

Maj-Britt Jensen, Torsten O Nielsen, John Bartlett

|Jan 29, 2025
Germline BRCA testing in Denmark following invasive breast cancer: Progress since 2000.

Aleksandar M Kostov, Maj-Britt Jensen, Bent Ejlertsen

|Oct 23, 2024
Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial.

Maj-Britt Jensen, Eva Balslev, Ann Søegaard Knoop

Pageof 3

Frequent Collaborators

11 joint publications

Bent Ejlertsen

4 joint publications

Deirdre P Cronin-Fenton

4 joint publications

Peer M Christiansen

3 joint publications

Anne-Vibeke Lænkholm